Skip to main content
ATHE
NASDAQ Life Sciences

Alterity Therapeutics Issues 18M Options, Signaling Near 100% Potential Dilution

Analysis by Wiseek.aiReviewed by Editorial Team
Sentiment info
Negative
Importance info
9
Price
$3.4
Mkt Cap
$61.757M
52W Low
$2.521
52W High
$7
Market data snapshot near publication time

summarizeSummary

Alterity Therapeutics has issued a substantial number of unlisted options under an employee incentive scheme. While not directly granted to key management personnel, the 18 million options represent a potential increase of nearly 100% in the company's US-equivalent shares outstanding, based on the current market capitalization and stock price. This level of potential dilution is highly significant and could materially impact the value of existing shares. The options' deeply in-the-money exercise price of AUD 0.008, compared to the current US stock price of $3.4, makes their eventual exercise highly probable, posing a considerable overhang on the stock.


check_boxKey Events

  • Issuance of Unlisted Options

    Alterity Therapeutics issued 18,000,000 unlisted options on January 15, 2026.

  • Employee Incentive Scheme

    The options were granted under an employee incentive scheme, not directly to key management personnel.

  • Significant Potential Dilution

    If exercised, these options represent a potential increase of nearly 100% in the company's US-equivalent shares outstanding, based on the current market capitalization and stock price.

  • Deeply In-The-Money Options

    The options have an exercise price of AUD 0.008 and expire in 2031, making them deeply in-the-money compared to the current US stock price of $3.40.


auto_awesomeAnalysis

Alterity Therapeutics has issued a substantial number of unlisted options under an employee incentive scheme. While not directly granted to key management personnel, the 18 million options represent a potential increase of nearly 100% in the company's US-equivalent shares outstanding, based on the current market capitalization and stock price. This level of potential dilution is highly significant and could materially impact the value of existing shares. The options' deeply in-the-money exercise price of AUD 0.008, compared to the current US stock price of $3.4, makes their eventual exercise highly probable, posing a considerable overhang on the stock.

في وقت هذا الإيداع، كان ATHE يتداول عند ‏٣٫٤٠ US$ في NASDAQ ضمن قطاع Life Sciences، مع قيمة سوقية تقارب ٦١٫٨ مليون US$. تراوح نطاق التداول خلال 52 أسبوعًا بين ‏٢٫٥٢ US$ و‏٧٫٠٠ US$. تم تقييم هذا الإيداع على أنه ذو معنويات سوقية سلبية وبدرجة أهمية ٩ من 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ATHE - Latest Insights

ATHE
Apr 27, 2026, 7:25 AM EDT
Source: GlobeNewswire
Importance Score:
8
ATHE
Apr 27, 2026, 6:21 AM EDT
Filing Type: 6-K
Importance Score:
8
ATHE
Apr 27, 2026, 6:21 AM EDT
Filing Type: 6-K
Importance Score:
8
ATHE
Apr 22, 2026, 6:03 AM EDT
Filing Type: 6-K
Importance Score:
8
ATHE
Apr 17, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
7
ATHE
Apr 16, 2026, 6:06 AM EDT
Filing Type: 6-K
Importance Score:
8
ATHE
Apr 15, 2026, 6:02 AM EDT
Filing Type: 6-K
Importance Score:
7
ATHE
Apr 01, 2026, 6:10 AM EDT
Filing Type: 6-K
Importance Score:
8
ATHE
Mar 30, 2026, 6:03 AM EDT
Filing Type: 6-K
Importance Score:
8
ATHE
Mar 19, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
9